In this randomized controlled trial we studied the haemodynamic effects of intravenous injection of lignocaine 1 mg/kg with either no additive, isoprenaline 0.05 µg or 0.075 µg/kg, or adrenaline 0.5 µg/kg in children anaesthetized with halothane. An increase of 10 bpm in heart rate or 20% rise in blood pressure was taken as a positive test response. Adrenaline was confirmed to be an unreliable marker with a positive test in only 67% of cases. For both doses of isoprenaline, the heart rate changes produced a positive test in 100% of cases. There was no statistically significant difference between the two doses of isoprenaline in regard to mean maximum increase in heart rate, mean time of beginning, ending or duration of positive test response and mean time to reach peak heart rate. The positive test response began between 10 and 50 seconds and lasted for an average of 69±54 seconds with the lower dose of isoprenaline 0.05 µg/kg. No advantage could be seen with the higher dose of isoprenaline. Change in blood pressure was not a useful criterion to detect intravascular injection. Recommendations for the use of isoprenaline as a marker of intravascular injection during regional blockade must be deferred until the safety of this agent's effect on neurological tissue is confirmed.
An epidural test dose containing adrenaline is recommended for detecting inadvertent intravascular injection of local anaesthetic before an epidural block. Epidural block in children is usually performed under general anaesthesia. Halothane is still commonly used for maintenance of anaesthesia in children. Volatile anaesthetics, especially halothane, may alter the haemodynamic responses to an intravascular injection of adrenaline 1 . Isoprenaline, a pure β agonist, has been suggested as an alternative marker in halothane anaesthetized children 2, 3 . Although isoprenaline appeared efficacious as a marker, the results of these studies varied as did the criterion for a positive test dose response. No published study has compared isoprenaline with adrenaline as test dose markers under identical anaesthetic conditions in matched groups of halothane anaesthetized children.
The present study was designed to assess the efficacy and reliability of adrenaline 0.5 µg/kg, isoprenaline 0.05 µg/kg and isoprenaline 0.075 µg/kg, as markers of intravenous injection. Intravascular injection during attempted epidural injection was simulated by intravenous injection of the study drug (including a placebo arm) with lignocaine 1 mg/kg in children anaesthetized with halothane under standard conditions.
MATERIALS AND METHODS
Institutional Ethics Committee approval was obtained and 60 unpremedicated ASA physical status 1 children of less than six years of age scheduled for elective surgical procedures were studied. Children suffering from heart disease, central nervous system disorders with raised intracranial pressure and those receiving β agonists, or antagonists, were excluded from the study. Informed consent was obtained from the parents. Children were kept fasting for four hours after the last liquid feed prior to surgery. Monitoring in the operating room included pulse oximetery, automated non-invasive blood pressure measurements, lead II electrocardiography and respiratory gas analysis. Anaesthesia was induced with halothane and nitrous oxide in 50% oxygen and intravenous access established. With the child spontaneously breathing 1% end-tidal halothane, it was ensured that all monitored parameters were stable for five minutes and end-tidal carbon dioxide was within the normal range. The baseline readings of heart rate, systolic and diastolic blood pressure were then recorded.
Children were divided randomly into four groups of 15 each. All subjects received lignocaine 1 mg/kg. Group LP (lignocaine plain) had no additive, group LA (lignocaine, adrenaline) had adrenaline 0.5 µg/kg added, whilst group LIL (lignocaine, isoprenaline lower dose) had isoprenaline 0.05 µg/kg added and group LIH (lignocaine, isoprenaline higher dose) had isoprenaline 0.075 µg/kg added. The test dose combination was prepared just before injection by mixing preservative-free lignocaine 2% solution (Xylocard™, AstraZeneca) in a volume of 0.05 ml/kg with appropriate calculated quantity of freshly diluted adrenaline or isoprenaline. The total volume of injection was kept constant at 0.1 ml/kg that resulted in a final lignocaine concentration of 1%. After baseline measurements were recorded (see above), the test drug was administered as an intravenous bolus at approximately 0.5 ml/second by one of the investigators who was unaware of the drug and dose, and haemodynamic parameters were recorded using automated monitors.
Heart rate was recorded from the ECG monitor with an updating interval of one second. The readings were noted for a total of 10 minutes, every 10 seconds for the first three minutes, every 30 seconds for the next two minutes and every minute thereafter for the remaining five minutes. The systolic and diastolic blood pressures were measured at one-minute intervals. All measurements were made under stable conditions with the child breathing 1% end-tidal halothane before intubation and surgical incision. An increase from baseline of 10 bpm in heart rate or 20% in blood pressure beginning within two minutes of injection was taken as clinically significant and was considered a positive response to the test dose.
Intragroup as well as intergroup analysis was done using analysis of variance (ANOVA) with Tukey test at 5% level and Fisher's exact test. Simple correlation at 5% level was done relating age, weight and basal heart rates to changes in the heart rate.
RESULTS
The patients were statistically similar in all four groups with regard to age, weight, gender ratio, baseline heart rate and blood pressure ( Table 1) . The youngest child was two months old and the oldest six years. There was a predominance of male subjects in all the groups with 80% males in LP, LIL and LIH and 60% in group LA.
Changes in Heart Rate
Injecting plain lignocaine 1 mg/kg (group LP) did not produce any marked changes in heart rate at any time after the injection ( Figure 1 ). The maximum rise seen was of the order of 1±4 bpm at 7 minutes while the maximum fall was 1±3 bpm at 90 seconds after the injection. Overall, the heart rate remained unchanged at ±5 bpm. Adrenaline in a dose of 0.5 µg/kg with lignocaine 1 mg/kg (group LA) produced a biphasic response, i.e., an initial tachycardia followed by bradycardia. The heart rate began to rise within 10 seconds and the mean values reached a peak at 30 seconds. This was followed by a fall to values lower than the basal rate that started from approximately 70 seconds and continued until the end of the observation period ( Figure 1 ).
Injecting lignocaine with isoprenaline in both low and high doses (groups LIL and LIH respectively) produced similar results, with an early increase in heart rate within 10 seconds of injection, and a peak at 50 seconds after the injection. The heart rate fell from peak levels but never reached basal values during the ten-minute observation period ( Figure 1 ). The mean change in heart rate in both these groups was statistically similar at all times. Changes in heart rate in all the groups at the end of the observation period were not different statistically when compared to the basal value within the group (P>0.05).
The maximum rise in heart rate during the first five minutes ranged from 1 to 6 bpm in group LP, 2 to 27 bpm in group LA, 11 to 45 bpm in LIL group and 13 to 70 bpm in group LIH ( Figure 2 ). The mean maximum increase in heart rate was 1±3 bpm, 13±10 bpm, 25±12 bpm and 26±14 bpm in the four groups respectively. The mean maximum increase in heart rate in the three groups containing vasoactive drug mixtures was statistically different to the plain lignocaine group (P<0.05). The differences between the adrenaline group and the two isoprenaline groups were also statistically significant. The two isoprenaline groups were not statistically different ( Table 2 ).
The range of times to peak heart rate in the first five minutes after injection was 10 to 300 seconds in group LP, 30 to 40 seconds in group LA, 40 to 100 seconds in group LIL and 30 to 60 seconds in group LIH. The mean time to peak heart rate was significantly longer in both the isoprenaline groups (51±16 s and 45±8 s) compared with the adrenaline group (35±5 s). The difference between the isoprenaline groups was not statistically significant ( Table 2) .
All the children in groups LIL and LIH had a positive test response in heart rate ( 10 bpm), compared with only 66% in group LA and none of the children in group LP (Figure 2) . Though the positive test response began at a statistically similar mean time in groups LA, LIL and LIH (P>0.05, Table 2 ), the mean duration of response was significantly less in the adrenaline group than the higher dose isoprenaline group. The difference in the test response duration between LA and LIL groups, though clinically markedly different, was not statistically significant. The difference was also not statistically significant between LIL and LIH groups. No arrhythmia was observed in any child in any group.
Changes in Systolic Blood Pressure
Plain lignocaine (LP) produced no significant change in systolic blood pressure (SBP) and none of the patients had an increase in SBP of 20% above baseline (positive response criteria in terms of blood pressure). Four patients had a fall in SBP (Figure 3 ). Injection of adrenaline with lignocaine caused an insignificant biphasic response in SBP with an initial rise in all the 15 patients (Figure 4 ). Only 10 children showed a positive test response in this group. All patients in the LIL and LIH groups had an increase in SBP, but only four of the LIL and two of the LIH group showed a rise of ≥20% (Figure 3) .
Changes in Diastolic Blood Pressure
No patient in group LP showed a positive diastolic blood pressure (DBP) test response, with four children having a decrease in DBP. A positive DBP test response occurred in nine of the LA group, five of the LIL group and four of the LIH group. A clinically insignificant biphasic response was shown by the LA and LIH groups .
DISCUSSION
A positive test response in our study was defined as an increase in heart rate of ≥10 bpm or an increase in systolic or diastolic blood pressures of ≥20% above basal values. It has been speculated that the cardiovascular effects of halothane, reduction in heart rate, myocardial contractility, cardiac output and arterial blood pressure, might minimize the response to injection of an adrenergic test dose. In the stable anaesthetized unstimulated child, an increase in heart rate of ≥10 bpm would be clinically significant and easily recognized on ECG. The threshold value for a positive test, 10 bpm rise in heart rate, was selected to minimize the number of false negative responses 1 . Perillo et al 2 also used the same criteria for a positive test response in children anaesthetized with halothane. In adults the criteria used have been quite variable ranging from increases of 8 bpm to 20 bpm above baseline [4] [5] [6] [7] [8] . To obviate the effect of pain and stress on haemodynamic parameters, intravenous access was established after induction of general anaesthesia and all the observations were completed before intubation and surgical incision. The dose of 1 mg/kg of lignocaine is well within the accepted safe dose for children. Adrenaline was used in a dose of 0.5 µg/kg (group LA). This dose is well below the range known to cause arrhythmias in children receiving halothane 1, 9 . The two doses of isoprenaline used in our study (0.05 µg/kg and 0.075 µg/kg) were within the lower end of the range that was tested in newborn lambs 10 and later advocated in other studies on children 2, 3 . Similar doses (if adjusted by estimated weight) have been used in adults 11 . Test solutions were freshly prepared, mixed and appropriately diluted in lignocaine just prior to injection. This was done because premixed preservative free solutions of lignocaine with adrenaline, and lignocaine with isoprenaline for intravenous use in desired dosages are not available.
Haemodynamic parameters were observed for a total period of 10 minutes. This was done because the duration of effect of adrenaline is five to 10 minutes and that of isoprenaline is one to five minutes. The heart rate was recorded at intervals of 10 seconds for the first three minutes and then progressively at longer intervals because the onset of action of both intravenous adrenaline and isoprenaline is rapid. The peak effect occurs within three minutes of injection for adrenaline and within one minute for isoprenaline. The ten second intervals for observing the heart rate aided precision in detecting the onset of a positive test response. Considering the pharmacokinetics, a positive test response was considered to be due to test drug only if it began within two minutes of injection. No correlation was found in the changes in heart rate, blood pressure or positive test response in any of the groups in relation to age, gender or weight.
Changes in Heart Rate
In group LP (lignocaine 1 mg/kg) the changes in heart rate were not significant and none of the children showed a positive test response ( Figure 2 ). These findings are consistent with the literature on changes in heart rate following lignocaine injection 1 . In group LA, all but one child showed an initial increase in heart rate. We could not explain the fall in heart rate seen in this child ( Figure 2 ). The mean changes in heart rate followed a biphasic pattern ( Figure 1 ). The literature is devoid of any study which has observed the changes in heart rate for a period of 10 minutes after injection of such a test dose in children. A biphasic response is a well documented pharmacodynamic effect of adrenaline 12 and has also been reported in halothane anaesthetized children 1 . The fall in heart rate below basal values, which began 70 seconds or later may have been due to the vagal stimulation 12 following the hypertensive response seen at 60 seconds in our study. In the study by Desparmet et al 1 , an initial rise was reported at 30 seconds and the peak at 45 seconds, but in their study, readings were taken at 15-second intervals. Similarly, the fall that was reported by them at 120 seconds probably lacked precision because of the longer inter-observation intervals of 30 to 60 seconds at this stage. However, the fall in heart rate at 180 seconds in our study was consistent with their observation.
The tachycardia induced in both LIL and LIH groups did not subside to the baseline until the end of the observation period ( Figure 1 ). Similar trends have been reported following the use of isoprenaline in halothane anaesthetized lambs 10 and children 2 . The rise in heart rate started at 10 seconds and the initial peak was at 50 seconds in both groups. The mean changes in heart rate in both the groups were comparable and not statistically different at any time.
The mean time to maximum heart rate was slightly longer in the LIL group than the LIH group (Table 2) . This is similar to findings reported by Perillo et al 2 and Langenecker and associates 3 . The mean maximum changes in heart rate in groups LIL and LIH (25±12 bpm and 26±14 bpm respectively) were significantly higher than in group LA (13±10 bpm). This result is similar to that of Langenecker and associates 3 (increases of 23±8 bpm and 29±9 bpm for the two isoprenaline doses), but Perillo et al 2 reported significantly different rises (16.5±8.7 bpm and 21.5±9.2 bpm) for the two isoprenaline doses.
A positive heart rate test response occurred no later than 40 seconds in groups LA and LIH and 50 seconds in group LIL. This suggests that the period of observation for a positive test should be 40 or 50 seconds, depending on the test solution. The duration of a positive response was significantly less in group LA (16±15 seconds) compared to group LIH (P<0.05). The duration of positive test response in the two isoprenaline groups was not statistically different (LIL 69±54 seconds and LIH 83±116 seconds P>0.05, Table 2 ). The increased duration of positive test responses in the LIL and LIH groups in comparison to LA group allows more time for detection of the response.
The adrenaline-containing test dose was positive in 67% of cases, similar to the 71% reported by Desparmet et al 1 with the same dose of adrenaline and criterion for a positive test response. A positive response was observed in 100% of cases with both doses of isoprenaline in our study in contrast to lower values reported by Perillo et al 2 and Langenecker et al 3 . Perillo, using the same criterion for a positive test response as we did, reported a positive response in 81% for 0.05 µg/kg isoprenaline and 95% for 0.075 µg/kg isoprenaline. Langenecker, using a rise of ≥20 bpm of heart rate as the criterion for a positive test, reported a positive response in 79% for 0.05 µg/kg isoprenaline and 89% for 0.075 µg/kg isoprenaline.
Since no statistically significant differences were found between the two doses of isoprenaline in terms of per cent positive responses, mean maximum increase in heart rate, time to reach maximum heart rate and time of beginning, end and duration of positive test response (P>0.05), there is no apparent advantage in using a higher dose of isoprenaline. Langenecker reported transient premature ventricular contractions in one of 19 children who received 0.075 µg/kg isoprenaline 3 . No arrhythmias were seen in any child in our study and similar findings have been reported by other authors 1, 2 . The lack of advantage and potential for arrhythmogenesis with the higher dose of isoprenaline suggests that the lower dose should be preferred.
